Mr. Weiner continued, "For the past few years we have been leveraging our expertise in our core business by broadening our content offerings. In the Film Production segment, we have begun production on the third season of a thirteen-episode series with a premium cable channel. We are also negotiating a new producer-for-hire agreement and are optimistic we will begin production for that film in the fourth fiscal quarter. These deals along with our recent entry into the mainstream DVD retail business should help drive long-term revenue growth for the Film Production segment. With respect to our IPTV project, we expect to launch key marketing initiatives in the third quarter of fiscal 2009 that will play an important role in calculating additional investment in this space. Looking ahead, we believe we have the resources in place to continue to be a leader in providing branded content to cable and satellite platforms and to expand our reach into promising new markets."

Second Fiscal Quarter Financial Highlights: September 30, 2008 Compared to September 30, 2007

    -- Net sales grew to $13.4 million as compared to $12.4 million.
       -- Transactional TV segment revenue grew to $10.8 million, increasing
          by approximately $0.8 million primarily from improved VOD
          performance on several of the top 10 largest cable MSOs in the U.S.
          The increase in revenue was partially offset by a $0.3 million
          decline from the termination of the C-Band services in the third
          quarter of fiscal year 2008.
       -- Film Production segment revenue grew to $2.2 million compared to
          $2.0 million, reflecting an increase in owned content revenue of
          approximately $0.3 million primarily from the delivery of seven
          titles from a thirteen episode series to a premium cable channel
          customer.  This increase was partially offset by a decline of
          $0.2 million in repped content revenue related to a softer global
          independent film market.
       -- Direct-to-Consumer segment revenue was $0.4 million for both
          periods.
    -- Cost of sales increased to $4.4 million from $3.5 million, primarily
       due to additional expenses associated with the set-top box initiative
       and an increase in the film cost amortization within the Film
       Production segment. The Transactional TV segment gross margin
       percentage of 73% was consistent with the same prior year period.
    -- Operating expenses increased to $6.8 million as compared to
       $5.7 million due to higher advertising and promotion costs within the
       Transactional TV segment, higher consultant advisory fees within the
       Corporate Administration segment, and from the set-top box initiative.
    -- Net income was $1.3 million, or $0.06 per diluted share, as compared to
       $2.1 million, or $0.09 per diluted share.
    -- Cash flow from operations grew to $1.5 million as compared to cash used
       in operations of $0.2 million. The prior year quarter results included
       $2.1 million of cash distributions related to a producer-for-hire
       production.

For the six months ended September 30, 2008, net sales grew to $26.4 million from $25.4 million in the same period last year. Net income was $2.5 million or $0.11 per diluted share, compared to $3.6 million or $0.15 per diluted share in the same prior year period. Cash flow from operations increased to $6.0 million from $0.9 million primarily due to a) the producer-for-hire cash disbursements, b) increased cash collections within the Transactional TV and Film Production segments, c) a decline in fiscal year 2008 bonuses paid during the first quarter of fiscal year 2009, and d) a decline in the use of cash for the Film Production segment content creation.

Non-GAAP Financial Measures

This press release contains non-GAAP financial measures as defined in Item 10 of Regulation S-K, including EBITDA and Adjusted EBITDA on a consolidated basis for the three and six month periods ended September 30, 2008 and 2007. The Company believes these measures provide useful information to management and to investors; however, these non-GAAP measures should be viewed in addition to, and not as an alternative for, the Company's reported results prepared in accordance with GAAP. A reconciliation of EBITDA and Adjusted EBITDA, as compared to the most directly comparable GAAP financial measure, net income, is presented in a reconciliation table that follows our presentation of Consolidated Operating Results below. EBITDA is calculated as net income plus depreciation, amortization, and income taxes, less other income; and Adjusted EBITDA is calculated as EBITDA less cash paid for content.

Conference Call Information

New Frontier Media, Inc. will be conducting its conference call and web cast to discuss earnings today at 11 a.m. Eastern Time. The participant phone number for the conference call is (800) 240-5318. To participate in the web cast please log onto http://www.noof.com and click on "Investor Relations" and then "Calendar of Events". A replay of the conference call will be available for seven days beginning after 1 p.m. Eastern Time on November 5, 2008 at (800) 405-2236, access code 11121990#. The replay will also be archived for twelve months on the corporate web site at http://www.noof.com. This press release can be found on the company's corporate web site, http://www.noof.com, under "Investor Relations/News Releases".

Cautionary Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on current expectations, estimates and projections made by management. These forward-looking statements are covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates", "expects", "intends", "plans", "believes'', "seeks", "estimates", or variations of such words are intended to identify such forward-looking statements. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. All forward-looking statements made in this press release are made as of the date hereof, and the Company assumes no obligation to update the forward-looking statements included in this news release whether as a result of new information, future events, or otherwise. Please refer to the Company's most recent Form 10-K and other filings with the Securities and Exchange Commission ("SEC") for additional information regarding risks and uncertainties, including, but not limited to, the risk factors listed from time to time in such SEC reports. Copies of these filings are available through the SEC's electronic data gathering analysis and retrieval (EDGAR) system at http://www.sec.gov.

ABOUT NEW FRONTIER MEDIA, INC.

New Frontier Media, Inc. is a leading producer and distributor of branded television networks and on-demand programming. The Company delivers nine full- time transactional adult-themed pay-per-view networks to cable and satellite operators across the United States. These services reach over 179 million network homes. Additionally, the Company is a leading provider of content to video-on-demand platforms on cable and satellite. New Frontier Media is the exclusive distributor of Penthouse branded adult television in the U.S. The Company's programming originates at New Frontier Media's state of the art digital broadcast center in Boulder, Colorado. The Company owns thousands of hours of digital content and partners with more than 130 movie studios to bring together a variety of transactional adult entertainment available today.

New Frontier Media's Film Production segment produces original motion pictures that are distributed in the U.S. on premium movie channels, such as Cinemax(R) and Showtime(R), and internationally on similar services. The Film Production segment also develops and produces exciting original event programming that is widely distributed on satellite and cable pay-per-view. Through the Lightning Entertainment(R) Group label, this segment also represents the work of a full range of independent U.S. film producers in markets around of the globe.

For more information about New Frontier Media, Inc. contact Grant Williams, Chief Financial Officer, at (303) 444-0900, extension 2185, and please visit our web site at http://www.noof.com.

    Consolidated Operating Results
    (in thousands, except per share amounts)


                                             (Unaudited)        (Unaudited)
                                             Quarter Ended    Six Months Ended
                                             September 30,     September 30,
                                             2008     2007     2008     2007

    Net sales                              $13,375  $12,430  $26,436  $25,370

    Cost of sales                            4,429    3,459    8,358    7,256

    Gross margin                             8,946    8,971   18,078   18,114

    Operating expenses                       6,800    5,719   13,946   12,723

    Operating income                         2,146    3,252    4,132    5,391

    Other income                                 9      149       31      385

    Income before provision for income
     taxes                                   2,155    3,401    4,163    5,776

    Provision for income taxes                (860)  (1,256)  (1,689)  (2,134)

    Net income                              $1,295   $2,145   $2,474   $3,642

    Basic income per share                   $0.06    $0.09    $0.11    $0.15

    Diluted income per share                 $0.06    $0.09    $0.11    $0.15

    Dividends declared per common share       $-      $0.13     $-      $0.25

    Average outstanding shares of common
     stock                                  23,202   24,120   23,445   24,232

    Common stock and common stock
     equivalents                            23,216   24,225   23,474   24,424



    EBITDA and Adjusted EBITDA

                                             (Unaudited)       (Unaudited)
                                            Quarter Ended    Six Months Ended
                                            September 30,     September 30,
                                            2008     2007     2008     2007

    Net Income                              $1,295   $2,145   $2,474   $3,642

    Adjustments:
      Other income                              (9)    (149)     (31)    (385)
      Provision for income taxes               860    1,256    1,689    2,134
      Depreciation and amortization          2,396    1,715    4,575    3,611
    EBITDA                                   4,542    4,967    8,707    9,002
      Cash paid for content(1)              (2,282)  (2,196)  (3,671)  (4,540)
    Adjusted EBITDA                         $2,260   $2,771   $5,036   $4,462

    (1) Amount includes total cash paid for prepaid distribution rights and
        capitalized film costs.



    Consolidated Balance Sheets
    (in thousands)
                                                 September 30,      March 31,
                                                     2008              2008
    Assets                                       (Unaudited)
    Current assets:
      Cash and cash equivalents                    $13,544           $18,325
      Restricted cash                                  109                38
      Marketable securities                          1,474               930
      Accounts receivable, net                      11,193            13,873
      Deferred tax asset                               601               620
      Prepaid and other assets                       1,384             1,899
    Total current assets                            28,305            35,685
    Equipment and furniture, net                     6,096             4,861
    Prepaid distribution rights, net                11,101            10,381
    Recoupable costs and producer advances           3,883             2,448
    Film costs, net                                  7,383             7,626
    Goodwill                                        18,608            18,608
    Other identifiable intangible assets, net        2,983             3,033
    Other assets                                     1,040             1,019
    Total assets                                   $79,399           $83,661

    Liabilities and shareholders' equity
    Current liabilities:
      Accounts payable                              $2,358            $2,937
      Dividend payable                                   -             2,982
      Taxes payable                                  1,944               760
      Producers payable                                957             1,012
      Deferred revenue                               1,257               984
      Accrued compensation                           1,448             1,817
      Deferred producer liabilities                  2,009             2,862
      Accrued liabilities and other                  3,068             2,257
    Total current liabilities                       13,041            15,611
    Deferred tax liability                             677               795
    Taxes payable                                      216               216
    Other long-term liabilities                        771             1,002
    Total liabilities                               14,705            17,624

    Commitments and contingencies

    Shareholders' equity:
      Common stock                                       2                 2
      Additional paid-in capital                    58,088            61,854
      Retained earnings                              6,665             4,191
      Accumulated other comprehensive loss             (61)              (10)
    Total shareholders' equity                      64,694            66,037
      Total liabilities and shareholders' equity   $79,399           $83,661



    Consolidated Statements of Cash Flows
    (In thousands)                                        (Unaudited)
                                                       Six Months Ended
                                                          September 30,
                                                     2008               2007
    Cash flows from operating activities:
    Net income                                     $2,474             $3,642
      Adjustments to reconcile net
       income to net cash provided by
       operating activities:
      Depreciation and amortization                 4,575              3,611
      Tax benefit from option/warrant exercises         -                167
      Share-based compensation                        537                563
      Deferred tax asset and liability, net           (99)              (508)
      Charge for asset disposition and impairment      65                363
    Changes in operating assets and liabilities
        Accounts receivable                         2,680                987
        Accounts payable                             (263)               195
        Prepaid distribution rights                (2,504)            (2,388)
        Capitalized film costs                     (1,167)            (2,152)
        Deferred costs                                  -             (2,106)
        Deferred revenue                              273                242
        Producers payable                             (55)              (411)
        Taxes receivable and payable                1,184                275
        Accrued compensation                         (369)            (1,547)
        Other assets and liabilities               (1,347)               (45)

              Net cash provided by
               operating activities                 5,984                888

    Cash flows from investing activities:
      Purchase of investments available-for-sale   (1,730)            (2,671)
      Redemption of investments available-for-sale  1,184              7,532
      Purchase of equipment and furniture          (2,222)            (1,160)
      Purchase of intangible assets                  (688)                 -
      Payment of related party note arising
       from business acquisition                      (21)              (555)

              Net cash (used in) provided
               by investing activities             (3,477)             3,146

    Cash flows from financing activities:
      Proceeds from exercise of stock
       options/warrants                                 -                512
      Purchase of common stock                     (4,303)            (3,618)
      Payment of dividend                          (2,982)            (6,042)
      Excess tax benefit from
       option/warrant exercise                          -                (26)

              Net cash used in
               financing activities                (7,285)            (9,174)

    Net decrease in cash and cash equivalents      (4,778)            (5,140)
    Effect of exchange rate changes on
     cash and cash equivalents                         (3)                 -
    Cash and cash equivalents,
     beginning of period                           18,325             17,345

    Cash and cash equivalents, end of period      $13,544            $12,205



    Segment Summary Data (1)
    (In millions)
                                (Unaudited)              (Unaudited)
                               Quarter Ended           Six Months Ended
                                September 30,            September 30,
                                 2008   2007   %change    2008   2007  %change
    Net sales
      Transactional TV           $10.8  $10.0    8%       $21.3  $20.4    4%
      Film Production              2.2    2.0   10%         4.2    4.1    2%
      Direct-to-Consumer           0.4    0.4    0%         0.9    0.9    0%
        Total net sales           13.4   12.4    8%        26.4   25.4    4%

    Cost of sales
      Transactional TV(2)          2.9    2.7    7%         5.5    5.5    0%
      Film Production              1.0    0.5    #          1.9    1.3   46%
      Direct-to-Consumer(2)        0.5    0.2    #          0.9    0.4    #
        Total cost of sales        4.4    3.5   26%         8.4    7.3   15%

    Operating expenses
      Transactional TV             2.4    2.1   14%         4.8    4.6    4%
      Film Production              1.1    1.0   10%         2.4    2.5   -4%
      Direct-to-Consumer           0.5    0.2    #          1.1    0.4    #
      Corporate Administration     2.7    2.4   13%         5.6    5.2    8%
        Total operating expenses   6.8    5.7   19%        13.9   12.7    9%

    Operating income (loss)
      Transactional TV             5.5    5.1    8%        11.0   10.2    8%
      Film Production               -     0.4    #           -     0.3    #
      Direct-to-Consumer          (0.7)   0.1    #         (1.2)   0.1    #
      Corporate Administration    (2.7)  (2.4) -13%        (5.6)  (5.2)  -8%
        Total operating income    $2.1   $3.3  -36%        $4.1   $5.4  -24%


    (1) Amounts in this schedule may not sum due to rounding.

    (2) The Company has reclassified certain prior year prepaid distribution
        rights amortization from the Transactional TV segment to the
        Direct-to-Consumer segment to conform with the current period
        presentation.

     #  Represents an increase or decrease in excess of 100%.



    Supplemental Revenue Data (1)
    (In millions)
                                 (Unaudited)              (Unaudited)
                                Quarter Ended          Six Months Ended
                                 September 30,           September 30,
                                 2008   2007   %change    2008   2007  %change

    Transactional TV(2)
    VOD                          $5.6   $4.7     19%      $10.8   $9.3    16%
    PPV                           5.0    4.9      2%       10.0   10.2    -2%
    C-Band and other              0.2    0.4    -50%        0.4    0.9   -56%
          Total                 $10.8  $10.0      8%      $21.3  $20.4     4%

    Film Production(3)
    Owned content                $1.7   $1.4     21%       $3.4   $2.8    21%
    Repped content                0.3    0.5    -40%        0.7    1.0   -30%
    Other                         0.1    0.1      0%        0.2    0.3   -33%
          Total                  $2.2   $2.0     10%       $4.2   $4.1     2%

    Direct-to-Consumer
    Net membership               $0.3   $0.3      0%       $0.7   $0.7     0%
    Other                         0.1    0.1      0%        0.1    0.2   -50%
          Total                  $0.4   $0.4      0%       $0.9   $0.9     0%


    (1) Amounts in this schedule may not sum due to rounding.

    (2) Prior year net revenue from advertising has been reclassified from
        PPV to C-Band and other revenue to conform with the current period
        presentation.

    (3) Other revenue was previously classified within owned content revenue
        and has been reclassified to conform with the current period
        presentation.

SOURCE New Frontier Media, Inc.

http://www.noof.com

(Logo: http://www.newscom.com/cgi-bin/prnh/20080325/SUBARULOGO )

Subaru upped the ante in the street performance arena for 2009 with a thoroughly revised 265 horsepower Impreza WRX. This year's WRX, in 4-door or 5-door models, hits the tarmac with more boost, power and a fully retuned suspension. On display at the SEMA Show this year is a new WRX upfitted with SPT parts, 18-inch wheels and a radical paint scheme.

The Forester XTI Concept combines the versatility of the all-new Forester 2.5XT with the all-out performance of the Impreza WRX STI. Forester was recently named MOTOR TREND magazine's Sport/Utility Vehicle of the Year for 2009.

The magazine applauded the new Forester's combination of performance, utility, comfort, safety technology and value in giving it the award. MOTOR TREND editor Angus MacKenzie, citing the judges' unanimous decision, said, "The Subaru Forester is the SUV for our times." In other award news, the Subaru 2.5-liter turbo Boxer engine -- variations of which power Impreza, Forester, Legacy and Outback models -- was named "International Engine of the Year" by a global panel of 65 judges.

Following is a rundown of the Subaru specialty vehicles for the 2008 SEMA Show:

2009 Forester XTI Concept

Can a vehicle be both wicked and practical? The Subaru Forester XTI answers with a roomy interior and a lot of turbo boost. This concept for an ultra-performance crossover utility vehicle inherits the full STI treatment. STI (Subaru Tecnica International), the high-performance and motorsports subsidiary of Fuji Heavy Industries Ltd., excels at designing race and street cars and the XTI concept blends both.

The "Wicked" Forester starts with more menacing styling, which is set off by a custom Atmospheric "Re-Entry" paint scheme. The front spoiler and Sport Mesh Grille are right from the Subaru Genuine Accessory catalog and are joined by a JDM body kit, including side skirts, a rear valence and a gate spoiler.

Built by Subaru of America technicians, the crew started with the engine and entire drivetrain from the WRX STI. In the Forester XTI, a custom stainless steel cat-back exhaust by Subaru Performance Tuning (SPT) helps to raise output of the 2.5-liter intercooled turbo engine to an estimated 315 hp (from 305 stock) and an estimated 300 lb.-ft. of torque (from 290 stock). As in the WRX STI, power flows through a close-ratio 6-speed manual transmission and the Driver Controlled Center Differential (DCCD) version of Subaru Symmetrical All-Wheel Drive. The DCCD system offers three selectable automatic performance modes in addition to six manual differential-locking settings.

The 18 x 8-in S204 forged alloy wheels are by STI and are wrapped in Yokohama Advan Neova 255/40R18 performance tires. The Forester XTI Concept also features the powerful Brembo brakes from the WRX STI, with 4-piston front calipers and 2-piston rear calipers, along with Super Sport ABS and Electronic Brake-force Distribution (EBD). Inside, the STI treatment adds leather and Alcantara sport seats, a special instrument cluster, front dash and center console and leather-wrapped steering wheel.

"Fast & Furious 4" WRX STI

Coming in June 2009, the debut of "Fast & Furious 4" features a muscled up Subaru WRX STI in the thick of the action. In this fourth installment of the successful film series, lead character Brian O'Connor (played by Paul Walker) is released from prison and helps the Feds bring down a heroin ring. His ride? A very special WRX STI patterned after the World Rally Car Concept.

A Vellside body kit and hood give the WRX STI a sinister look, reinforced by custom black and silver paint with red pin striping by Jack's Auto Body. Eukei NT03+M wheels mount 285/40 R18 Continental Sport Contact 2 tires.

The movie car features a mostly stock factory powertrain, with a Perrin intake, Cobb Tuning ignition and 3-in. Cobb exhaust to unleash a few more horses from the 2.5-liter turbocharged / intercooled Boxer engine. A twin-plate clutch and Vellside shifter reinforce the drivetrain, which retains the stock DCCD Symmetrical All-Wheel Drive system.

The Fast & Furious interior gets a rally look and feel with Vellside seats and steering wheel, a custom rollcage and Takata seatbelts. The movie arrives in theaters June 12. The bad guys don't stand a chance.

2009 Forester Mountain Rescue Concept

Subaru is the Official Vehicle of the National Ski Patrol for good reason -- Symmetrical All-Wheel Drive, robust construction and durability make any Subaru ideally suited to tough winter conditions. Working with Subaru of America and the National Ski Patrol, Detroit-based Specialized Vehicles built a special Forester as the ultimate first responder. Based on the award-winning Forester 2.5XT turbo crossover utility vehicle, the Forester Mountain Rescue Concept is designed to help crews conduct rescues in difficult terrain and weather conditions.

In stock form, the 2009 Forester 2.5XT starts off with nearly 9 inches of ground clearance -- more than other crossovers and SUVs. But rescue crews often need more, and this vehicle boasts more than 14-in. of ground clearance via a custom adjustable ride height air suspension system by Air Lift. Additional off-road and snow traction is provided by Yokohama Geolander MTS 30 x 9.5-in. tires on special 15-in. Subaru custom-reversed near-zero offset steel wheels.

Additional trail protection comes from custom front and rear skid plates by DeeZee and custom Trail Armor by Bushwacker, including fender flares, lower door cladding and, a rear gate guard and tail light guards.

You won't have trouble seeing the Forester Mountain Rescue Vehicle coming: an emergency light package, augmented by Subaru Genuine Accessory Baja Sport Activity Lights, ensures visibility for long distances and in difficult weather. To illuminate a rescue location, the vehicle is equipped with roof mounted Visi Light LED spotlights -- five in front and two in the rear -- by Hamsar Diversco.

Once on the rescue site, the crew can use an Ultimate Performance 9.5i Thermometric 9,500-lb. winch by WARN. Remote rear door openers and external quick-access utility compartments play a vital role when time is of the essence. Extra wide round crossbars help secure the Subaru Yakima ski carriers, which on this vehicle hold Nordica snow skis. A rescue toboggan from Cascade rounds out the equipment. Topping off the distinctive styling, a DeeZee custom grille guard helps protect the Sport Mesh Grille from Subaru Genuine Accessories.

2009 Impreza WRX 5-door SPT

How far can you take an Impreza WRX using parts from the Subaru Genuine Accessory and SPT catalogs? Pretty far, it turns out. Subaru mined both catalogs to come up with a combination of performance, styling and user technology that any enthusiast could easily duplicate -- all at once or by adding parts over time. The resulting car makes a unique performance and design statement while remaining true to the WRX's everyday drivability character and value.

The 2009 Impreza WRX already comes with a standard factory Aero Body Kit, so external mods were limited to a front lip spoiler by STI and Subaru genuine Accessory fog light protectors.

The more hunkered-down stance is courtesy of STI performance springs and Botticelli III 19x8-in. wheels by OZ Racing. A lower chassis brace and strut tower brace from the SPT catalog round out the chassis mods.

Subaru boosted the WRX's 2.5-liter intercooled turbo Boxer engine to 265 hp 244 lb.-ft. for 2009; this special WRX raises that to 275 hp and 250 lb.-ft. with a SPT cat-back exhaust. The driver can make the most of the power with the help of an STI short-throw shifter. The under-hood area gets a visual boost with an SPT oil cap, turbo heat shield and battery hold-down.

2009 Impreza WRX by AEM

Californian enthusiasts take their surfing and snowboarding as seriously as their souped-up Subarus. Noted Subaru tuner AEM has cooked up a tarmac monster based on the 2009 WRX to get them to the beach in the morning and mountains in the afternoon -- and in a hurry thanks to a turbo Boxer engine that delivered 449 horsepower and 411 lb.-ft. of torque on the dyno. The custom snowboard carrier by Subaru Yakima and surfboard carrier from Yakima carry an equally custom snowboard by Revolution and a surfboard from Hori Boards. A Revolution skateboard is thrown in for good measure.

Under hood, it's a smorgasbord of power parts from AEM, SPT, STI and other notable suppliers. The complete power makeover includes a Garrett GT3582R turbo with V44 wastegate and 50-mm blow-off valve from Tial Sport, Deatschwerks 850-cc injectors, and a programmable engine management system and water injection system from AEM. Playing vital supporting roles are the stock, reversed intake manifold, a front-mount intercooler kit and air/oil separator from Harman Motive, AEM Dryflow air filter and sensors and an in-tank Walbro fuel pump. Various dress-up parts from SPT and STI complete the engine package, and an SPT cat-back exhaust gives this car its signature snarl.

The chassis is thoroughly beefed up with SPT and STI parts, highlighted by an adjustable coil-over suspension from STI. Volk Racing GTV 18-in. wheels carry Toyo Proxes tires, and the car sports a 330-mm Prodrive front brake conversion.

The AEM WRX interior deftly blends racing seats and safety components from Sparco and high-power Clarion audio installation by Creative Car Audio & Motorsports. Mobworks sprayed the custom flat white pearl paint, and Sticky Fingers provided custom decals.

Subaru SRRT Legacy spec.B Koni Challenge

The Subaru Legacy 2.5GT spec.B is the perfect platform for the Grand-Am KONI Challenge Race, as the Subaru Road Racing Team (SRRT) has shown. Prepared by ICY/Phoenix Racing, the Legacy spec.B shows how easily this sedan with Symmetrical All-Wheel Drive adapts to track duty. Its stock 2.5-liter turbo Boxer engine makes 250 hp and 250 lb.-ft. of torque with the factory exhaust (catalyst removed). The driveline is beefed up with Carbonetic front and rear differentials and a custom transmission cooler.

The chassis is race-prepped using JRZ 3-way coil-over adjustable shocks, an STI strut tower bar, and rear camber links and a 25-mm rear stabilizer bar from Perrin. Brakes are factory with Hawk pads. The racing seats and steering wheel are from Sabelt.

Crawford Performance Unlimited Class Time Attack WRX STI

As Time Attack popularity grows, the Subaru WRX STI stands out as an ideal competitor. Crawford Performance has built a Time Attack monster powered by a specially built 500-hp turbo Boxer engine with an equally amazing 500 lb.-ft. of torque. It's based on a Billet SR6 2.65-liter Subaru race motor with a full complement of performance parts from Crawford, including the cylinder heads and CP35R turbo kit. Feeding the beast are 800-cc injectors and a cold air intake from Crawford, with engine management by MoTeC (tuned by Crawford). The engine exhales through a Crawford race exhaust.

The chassis is prepped with Super Racing coilovers and springs from TEIN, along with Crawford rear lateral links. Brembo Gran Turismo brakes replace the stock units. The Crawford STI claws its way around the track on Hankook tires mounted to 18-in. Volk Racing wheels.

Subaru Rally Team USA Open Class Rally Car

Subaru enthusiasts appreciate the value of the brand's rally heritage in the current WRX and WRX STI models. This season marks the debut of the all-new 2008 Subaru Impreza WRX STI rally car in the Rally America National Championship. Subaru Rally Team USA runs two Open Class WRX STI rally cars, with drivers Travis Pastrana (#199) and Ken Block (#43).

Several elements of the second-generation WRX STI make it an ideal base for a rally car: a longer wheelbase for improved straight-line movement, a wider track for increased maneuverability, and double wishbone rear suspension for better road holding capabilities. The team's technical partner, Vermont SportsCar, begins with a stock Subaru Impreza WRX STI. The car's interior is then stripped bare and the shell lightened and then fully seam-welded for added strength. A multipoint roll cage, manufactured from T45 steel, is welded into place.

Racing equipment includes a competition fuel cell and lightweight carbon/Kevlar RECARO SPA ProRacer competition seats with the Head and Neck Restraint System (HANS). Other interior additions include a custom STI dashboard, carbon fiber door panels, a Coralba C-Giant rally odometer, and an onboard fire suppression system.

A 2.0-liter turbocharged and intercooled STI Boxer engine produces 303 horsepower, just two under the stock WRX STI, and 451 lb.-ft. of peak torque, about 50 percent more than the street car. Launch control, a turbo anti-lag system and a hydraulic handbrake are just a few of the rally-specific tools at the driver's disposal. The stock dampers are swapped out for heavy-duty adjustable rally dampers made by exe-tc competition suspension.

A 5-speed, close-ratio dog-engagement gearbox allows the driver to shift without using the clutch. The DCCD (Driver Controlled Center Differential) is used in a similar way to a stock WRX STI, but with a competition ECU that allows for greater control of the torque delivery among all four wheels. The exterior of the car remains close to stock, with the simple addition of mud flaps and a 1/4-inch aluminum skid plate. A roof-mounted air scoop provides cooling air to the driver and navigator.

2009 Subaru Legacy 3.0R Limited by harmon-kardon(R)

Most 2009 Subaru Legacy and Outback models are standard-equipped with a premium audio system from harmon-kardon. For the SEMA Show, the audio brand put together a very special Legacy that showcases some of its best amplifiers, as well as speakers from sister brand JBL.

The exterior gets a thorough makeover using JDM front fascia, fenders and hood, along with JDM HID projector beam headlights. The 18 x 7.5-in. STI wheels carry Yokohama Neova tires. Inside, custom brushed aluminum trim bezels for the speakers highlight the elegant Legacy interior styling.

A performance exhaust system by SPT adds some more bark to the bite of the stock 245-hp 3.0-liter 6-cylinder Boxer engine. A coil-over suspension by STI sharpens the car's back road moves, and STI brake components enhance stopping power.

About Subaru of America, Inc.

Subaru of America, Inc. is a wholly owned subsidiary of Fuji Heavy Industries Ltd. of Japan. Headquartered in Cherry Hill, N.J., the company markets and distributes Subaru Symmetrical All-Wheel Drive vehicles, parts and accessories through a network of nearly 600 dealers across the United States. Subaru makes the best-selling All-Wheel Drive car sold in America based on R.L. Polk & Co. new vehicle retail registration statistics calendar year-end 2007. In addition, Subaru boasts the most fuel efficient line-up of all-wheel drive products sold in the market today based on Environmental Protection Agency (EPA) fuel economy standards. All Subaru products are manufactured in zero-landfill production plants and Subaru of Indiana Automotive Inc. is the only U.S. automobile production plant to be designated a backyard wildlife Habitat by the National Wildlife Federation. For additional information visit http://www.subaru.com.

    Contact:    Dominick Infante
                Subaru of America, Inc.
                (856) 488-8615
                dinfante@subaru.com

                Jessica Tullman
                Subaru of America, Inc.
                (310) 352-4400
                jtullman@subaru.com

SOURCE Subaru of America, Inc.

http://www.subaru.com

http://www.reportlinker.com/p096379/Women's-Health-Diagnostic-Testing.html

The purpose of this TriMark Publications report is to describe the specific segment of the in vitro diagnostics (IVDs) market called women's health testing. This study includes contemporary and generally accepted clinical and analytical activities. This analysis examines clinical measurement devices, as well as their reagents and supplies, as utilized in hospitals, clinics and doctor's offices. Some diagnostic tests, which are marketed primarily as over-the-counter products, are included in this report.

This report also includes other important tests like mammography, (i.e., tests which are not generally associated with IVD tests, but which are an important component of the overall women's health market).

This study deals with analysis related to the common chemical constituents of blood, plasma or serum of concern to patient testing in the field of women's health. Emphasis is on those companies and products that are actively developing and marketing clinical laboratory instrumentation, reagents and supplies for performing diagnostic tests related to women's health. This study concentrates on the women's health testing market segment in important worldwide markets such as the U.S., Japan and Europe.

1.0 Overview
1.1 Statement of Report
1.2 Scope of this Report
1.3 Methodology
1.4 Executive Summary
2.0 Introduction - Sector Overview
2.1 Global Diagnostic Products Industry
3.0 Women's Health Testing Market Analysis in Size, Growth and Share
3.1 Global Women's Health Testing Markets


3.1.1 Market Drivers in the Women's Health Diagnostics Testing Sector


3.1.1.1 Market Segments for Women's Health Testing
3.1.1.2 Key Players in the Women's Health Diagnostics Testing Segment
3.1.1.3 Women's Health Testing Sector Analysis

3.2 U.S. Women's Health Testing Market


3.2.1 Market Overview
3.2.2 Diagnostic Test Categories

3.3 European Women's Health Diagnostic Test Market


3.3.1 German Women's Care Diagnostic Market
3.3.2 U.K. Women's Care Testing Diagnostic Market


3.3.2.1 U.K. Market Statistics
3.3.2.2 U.K. Competitive Analysis
3.3.2.3 U.K. Market Access

3.3.3 French Women's Care Diagnostic Market
3.3.4 Italian Women's Care Diagnostic Market
3.3.5 Spanish Women's Care Diagnostic Market

3.4 Japanese Women's Care Testing Market
3.5 Chinese Women's Care Market
3.6 Rest of the World Women's Care Testing Market
4.0 Women's Health Testing Individual Markets
4.1 Pregnancy Testing
4.2 Osteoporosis Testing


4.2.1 In Vitro Blood Tests
4.2.2 Bone Densitometry Devices

4.3 Prenatal Screening Testing


4.3.1 Cystic Fibrosis
4.3.2 Prenatal Genetic Testing
4.3.3 Fragile X Syndrome
4.3.4 Tay-Sachs Disease

4.4 Fertility Testing
4.5 Breast Cancer


4.5.1 CA 15-3
4.5.2 CA 27-29
4.5.3 BRCA1 Breast and Ovarian Cancer Gene
4.5.4 BRCA2 Breast Cancer Gene
4.5.5 Tissue polypeptide antigen (TPA)
4.5.6 DNA Ploidy and S-phase Fraction
4.5.7 Estrogen and Progesterone Receptor (ER and PR)
4.5.8 HER-2
4.5.9 HER-2 and Herceptin
4.5.10 p53
4.5.11 NMP66
4.5.12 Mammastatin

4.6 Ovarian Cancer


4.6.1 CA 125 II(TM)
4.6.2 Steroid Hormone Receptors
4.6.3 Epidermal Growth Factor Receptor (EGFR)
4.6.4 HER-2/neu
4.6.5 P53 Tumor Suppressor Gene
4.6.6 Lysophospholipids

4.7 Cervical Cancer


4.7.1 Pap Smears
4.7.2 Human Papillomavirus (HPV) Testing

4.8 Miscellaneous Testing


4.8.1 Estriol
4.8.2 Fetal Fibronectin (fFN)
4.8.3 Vaginal pH and Vaginitis

4.9 Human Immunodeficiency Virus (HIV)
4.10 Infectious Disease Testing


4.10.1 Strep Testing
4.10.2 Chlamydia
4.10.3 Methicillin-Resistant Staphylococcus Aurea (MRSA)
4.10.4 Hepatitis
4.10.4 Gonorrhea
4.10.5 Urinary Tract Infections
4.11 Infant Jaundice

5.0 World Mammography Market
5.1 Mammography Overview
5.2 Market Overview


5.2.1 Introduction
5.2.2 World Mammography Markets Revenue
5.2.3 Mammography Markets by Region
5.2.4 Total Market Share
5.2.5 Competitive Structure

5.3 Market Opportunities


5.3.1 Resource Management for Mammography Markets
5.3.2 Movement to Higher Reimbursement Rates
5.3.3 Market Benchmarks for Increased Mammography Utilization

5.4 Market Analysis


5.4.1 Strategic Partnerships
5.4.2 Long Term Trends

5.5 Strategic Outlook


5.5.1 Competitive Elements of Mammography Markets
5.5.2 Higher Reimbursement Rates
5.5.3 Volume Requirements
5.5.4 Product Innovation
5.5.5 Product Leadership
5.5.6 Product Line Strategy
5.5.7 Pricing Strategy & Reimbursement
5.5.8 Strategic Partnerships

5.6 Film-Based Mammography Market


5.6.1 Market Overview


5.6.1.1 Unit and Revenue Forecasts
5.6.1.2 Product Analysis

5.6.2 Market Drivers
5.6.3 Market Restraints
5.6.4 Film-Based Mammography Market and Technology Trends
5.6.5 U.S. Market for Film-Based Screening Systems


5.6.5.1 Unit Shipment and Revenue Forecasts
5.6.5.2 Competitive Analysis
5.6.5.3 U.S. Installed Base Analysis

5.6.6 European Market for Film-Based Mammography Systems


5.6.6.1 Unit Shipment and Revenue Forecasts
5.6.6.2 Competitive Analysis
5.6.6.3 Installed Base Analysis
5.6.7 Japanese (Pacific Rim) Market for Film-based Mammography Systems
5.6.7.2 Competitive Analysis
5.6.7.3 Installed Base Analysis

5.6.8 Rest of the World Market for Film-based Mammography Systems


5.6.8.1 Unit Shipment and Revenue Forecasts
5.6.8.2 Installed Base Analysis

5.7 Digital X-Ray Mammography Market


5.7.1 Digital Mammography Overview
5.7.2 Market Overview
5.7.3 Product Background
5.7.4 Product Description
5.7.5 Market Drivers
5.7.6 Market Restraints
5.7.7 Unit Shipment and Revenue Forecasts
5.7.8 Percentage Breakdown of Revenues by Region
5.7.9 Market Share
5.7.10 U.S. Market for Digital Mammography Systems


5.7.10.1 U.S. Sales
5.7.10.2 Competitive Analysis

5.7.11 European Market for Digital Mammography Systems


5.7.11.1 Unit Shipment and Revenue Forecasts
5.7.11.2 Competitive Analysis
5.7.11.3 Installed Base Analysis

5.7.12 Japanese (Pacific Rim) Market for Digital Mammography Systems
5.7.12.1 Unit Shipment and Revenue Forecasts


5.7.12.2 Competitive Analysis
5.7.12.3 Installed Base Analysis

6.0 Women's Health Testing: Growth Regulators
6.1 Moderators of Growth
6.2 Personnel Acceptance
6.3 Key People for Women's Health Testing
6.4 Key Elements for Women's Health Testing
6.5 Women's Health Testing and Reimbursement
6.6 Rapid Near-Patient Testing in Hospitals
6.7 Satellite Facilities
6.8 Regionalization of Laboratory Care
6.9 Requirements for Women's Health Testing
6.10 Clinical Laboratory Improvement Act of 1988 (CLIA)
7.0 Business Trends in the Industry
7.1 Sector Consolidation
7.2 Diagnostic Testing Growth Trends
7.3 Acquisition, License Agreements, Internal Development and Partnerships
7.4 Product Testing Depth in Women's Health Testing
7.5 Government Regulation


7.5.1 U.S. Regulation


7.5.1.1 Importing Medical Devices into the U.S.
7.5.1.2 Exporting Medical Devices from the U.S.

7.5.2 U.K. Regulation
7.5.3 E.U. Regulation
7.5.4 Japanese Regulation

7.6 Increased Market Penetration
7.7 Legal Issues
8.0 Important Technology Trends
9.0 Company Profiles
9.1 Abbott Diagnostics
9.2 Accurex Biomedical, Pvt., Ltd
9.3 Adeza Biomedical Corporation (Acquired by Hologic)
9.4 Agfa-Gevaert Corporation
9.5 Ambri Ltd.
9.6 American Biomedica Corp.
9.7 Avitar Inc.
9.8 Axis-Shield
9.9 Bayer Corporation Diagnostics Division (Acquired by Siemens)
9.10 Becton Dickinson
9.11 Biomerica
9.12 Carestream Health
9.13 CMT Medical Systems
9.14 Cozart Biosciences (Acquired by Concateno PLC)
9.15 Cytyc Corporation
9.16 Dalsa
9.17 Denka Seiken Co., Ltd.
9.18 DiaDexus LLC
9.19 Enterix, Inc. (Acquired by Quest Diagnostics)
9.20 Fischer Imaging (Acquired by Hologic)
9.21 FujiFilm Medical Systems
9.22 General Electric Healthcare
9.23 Genzyme Diagnostics
9.24 Hologic Inc.
9.25 iCAD, Inc.
9.26 Imaging Diagnostic Systems Inc.
9.27 Inverness Medical Innovations
9.28 Johnson & Johnson
9.29 Kyowa Medex Co., Ltd.
9.30 L-3 Titan Group
9.31 LifePoint, Inc.
9.32 LifeScan Corporation
9.33 Matritech
9.34 Medix Biochemica
9.35 Mitsubishi Kagaku Iatron
9.36 Myraid Genetics
9.37 OraSure Technologies, Inc.
9.38 Polymedco
9.39 Procrea
9.40 QIAGEN
9.41 Quidel
9.42 Rad-Icon Imaging Corp
9.43 Roche Diagnostics
9.44 Scanis Inc.
9.45 Sectra Imtec AB
9.46 Shanghai Kehua Bioengineering Co., Ltd.
9.47 Siemens Healthcare
9.48 TriPath Imaging (Acquired by BD)
9.49 Vidar Systems Corp.
10.0 Appendices
10.1 Digital Database for Screening Mammography (DDSM)
10.2 Sources of National Cancer Institute Information
10.3 Screening Mammograms: Questions and Answers
10.4 FDA Rule: State Certification of Mammography Facilities
INDEX OF TABLES
Table 2.1: Worldwide Market Share In Vitro Diagnostic Companies
Table 2.2: Worldwide In Vitro Diagnostics Market Size, 2001-2012
Table 2.3: Worldwide In Vitro Clinical Laboratory Diagnostic Testing
 2003-2012
Table 2.4: Worldwide Point-of-Care Diagnostic Testing 2001-2012
Table 3.1: Top Drugstore Retailers in the U.S.
Table 3.2: Top Drugstore Wholesalers in the U.S.
Table 3.3: U.S. Women's Health Diagnostics Products Market Sales 2000-2012
Table 3.4: U.S. Clinical Diagnostic Women's Test Market Segments 2005
Table 3.5: Regional Comparison Healthcare and IVD
Table 3.6: European Women's Care Testing Market, 2000-2012
Table 3.7: European Women's Care Testing Diagnostics Market
Table 3.8: German Women's Care Testing Diagnostics Products Market Sales,
2000-2012
Table 3.9: The German Patient Care Laboratory Test Market, 2000-2012
Table 3.10: The German Alternate Site Testing Market, 2000-2012
Table 3.11: The German Hospital Point of Care Market, 2000-2012
Table 3.12: German Clinical Diagnostic Rapid Women's Test Market Segments
Table 3.13: U.K. Women's Health Diagnostics Products Market Sales,
 2006-2012
Table 3.14: Major U.K. IVD Manufacturers
Table 3.15: U.S. IVD Manufacturers Doing Business in the U.K.
Table 3.16: Other European Companies that Manufacture IVD Products in
 the United Kingdom
Table 3.17: French Women's Health Diagnostics Products Market Sales,
 2000-2012
Table 3.18: Italian Women's Health Diagnostics Products Market Sales,
 2000-2012
Table 3.19: Spanish Women's Heath Diagnostics Products Market Sales,
 2000-2012
Table 3.20: Japan Women's Care Testing Market, 2000-2012
Table 3.21: Chinese Women's Care Diagnostics Products Market Sales,
 2000-2012
Table 3.22: The ROW Women's Care Testing Market, 2000-2012
Table 4.1: U.S. Women's Health Testing Pregnancy Testing Market,
 2001-2012
Table 4.2: U.S. Market Share for Rapid Women's Health Testing
 Pregnancy Tests
Table 4.3: The Pregnancy Test Market for OTC Testing in the U.S.,
 2000-2012
Table 4.4: Home Pregnancy Tests Available in the U.S. Market
Table 4.5: Osteoporosis Risk Factors that Cannot Be Changed
Table 4.6: Osteoporosis Risk Factors that Can Be Changed
Table 4.7: Prenatal Screening Types
Table 4.8: History: Parental Genetic Traits
Table 4.9: Female Factor Infertility
Table 4.10: Frequency of Mutation Based Upon Ethnicity
Table 4.11: Reasons for CF Testing
Table 4.12: CF Testing Methodology
Table 4.13: CF Gene Detection Rates Vary by Ethnic Background
Table 4.14: Global Market for CF Diagnostic Testing, 2000-2012
Table 4.15: U.S. Market for CF Diagnostic Testing, 2000-2012
Table 4.16: Commercial CF Screening Products
Table 4.17: Emerging CF Screening Products
Table 4.18: CF Screening Technology Summary
Table 4.19: Genetic Screening During Pregnancy
Table 4.20: Ultrasound Screening
Table 4.21: Future Trends in Prenatal Genetic Testing, 2000-2012
Table 4.22: Ovulation Predictors
Table 4.23: TPA Marker Sensitivity
Table 4.24: HPV Risk Factors
Table 4.25: Relationship between HPV and Cervical Carcinoma
Table 4.26: HPV and Cervical Carcinoma Risk
Table 4.27: Rationale for Reflex HPV Testing with Cytology
Table 4.28: Rationale against Reflex HPV Testing with Cytology
Table 4.29: Predictability of HPV Test by Abnormal Pap Smear Type
Table 4.30: Incidence of Cervical Cancer and Cytological Abnormalitie
Table 4.31: Long Term Trends in HPV Testing
Table 4.32: U.S. Women's Health Testing Market for HIV, 2001-2012
Table 4.33: Countries with the Highest Prevalence of HIV / AIDS
Table 4.34: Births of HIV Infected Babies in U.S., 2002-2006
Table 4.35: U.S. Strep Testing Market Size, 2002-2012
Table 4.36: U.S. Market for Rapid Point of Care Strep Tests
Table 4.37: The U.S. Chlamydia Testing Market, 2000-2012
Table 4.38: Summary of Hepatitis Test Technology
Table 5.1: U.S. Healthcare Expenditures, 2000-2010
Table 5.2: International Per Capita Healthcare Spending by Country, 2006
Table 5.3: U.S. Use of Mammography in Women Over 40, 1987-2005
Table 5.4: Annual Mammography Procedures in the U.S., 2000-2008
Table 5.5: Annual Mammography Procedures in Europe, 2002-2007
Table 5.6: Annual Mammography Procedures in Japan, 2002-2007
Table 5.7: Annual Mammography Procedures in the Rest of the World,
 2002-2007
Table 5.8: U.S. Mammography Facts, 2005
Table 5.9: Breast Cancer Survival Rates by Country
Table 5.10: Surgical Biopsies Performed in the U.S., 2000-2007
Table 5.11: The Worldwide Mammography Instrument Market, 2000-2010
Table 5.12: Worldwide Mammography Instrumentation Placements, 2002-2010
Table 5.13: Worldwide Film-Based Mammography Instrumentation Placements,
 2002-2010
Table 5.14: Worldwide Mammography Film-Based Instrument Market, 2000-2010
Table 5.15: Worldwide Mammography Film-Based Instrument Market by Region,
 2000-2010
Table 5.16: U.S. Mammography Film-Based Instrument Market, 2000-2010
Table 5.17: U.S. Mammography Film-Based Instrument Market Manufacturer
 Share
Table 5.18: U.S. Film-Based Mammography Instrumentation Placements,
 2002-2010
Table 5.19: European Mammography Film-Based Instrument Market, 2000-2010
Table 5.20: European Film-Based Mammography Instrumentation Placements,
 2002-2010
Table 5.21: European Mammography Film-Based Instrument Market Manufacturer
 Share
Table 5.22: Japanese Mammography Film-Based Instrument Market, 2000-2010
Table 5.23: Japanese Film-Based Mammography Instrumentation Placements,
 2002-2010
Table 5.24: Japanese Mammography Film-Based Instrument Market Manufacturer
 Share
Table 5.25: ROW Mammography Film-Based Instrument Market, 2000-2010
Table 5.26: ROW Film-Based Mammography Instrumentation Placements,
 2002-2010
Table 5.27: Advantages of Digital Mammography
Table 5.28: Worldwide Digital General Radiography Market, 2000-2012
Table 5.29: Worldwide Market for Digital Mammography Systems Annual
 Unit Sales, 2000-2010
Table 5.30: Worldwide Market for Digital Mammography Systems, 2000-2010
Table 5.31: Worldwide Mammography Digital Instrumentation Placements,
 2002-2010
Table 5.32: Worldwide Mammography Digital Instrument Market by Region,
 2001-2010
Table 5.33: Share of Worldwide Market for Digital Mammography Systems by
 Competitor
Table 5.34: U.S. Mammography Digital Instrument Market, 2001-2010
Table 5.35: U.S. Digital Mammography Instrumentation Placements, 2002-2010
Table 5.36: European Mammography Digital Instrument Market, 2001-2010
Table 5.37: European Digital Mammography Instrumentation Placements,
 2002-2010
Table 5.38: Japanese Mammography Digital Instrument Market, 2001-2007
Table 5.39: Japanese Digital Mammography Instrumentation Placements,
 2002-2010
Table 9.1: Products Marketed By Abbott in the Diagnostic Market

To order this report:

Women's Health Diagnostic Testing

http://www.reportlinker.com/p096379/Women's-Health-Diagnostic-Testing.html

More market research reports here!

SOURCE: Reportlinker.com

Reportlinker.com
Nicolas
US: (805) 652-2626 or Intl: +1-805-652-2626
Email: nbo@reportlinker.com

-- Record digital revenue of $8.2 million, up 104%

-- Film based revenue of $2.2 million, up 48%

-- Record gross margin of 84.1%, up more than 400 basis points

-- Net income of $2.1 million, or $0.04 per diluted share

-- Fifth consecutive quarter with positive cash flow

Other highlights of the quarter include:

-- Unveiling of SpectraLook(TM) and CADvue(TM), two new Breast MRI products, and the new VividLook Prostate MRI product for introduction to the marketplace.

-- Launch of SecondLook(R) Digital CAD for use with Sectra's MicroDose Mammography(TM) system in Europe.

-- Closing of the asset acquisition of CAD Sciences, acquiring pharmacokinetic-based CAD products that aid in the interpretation of contrast-enhanced Magnetic Resonance Imaging (MRI) images of the breast and prostate.

-- Ranked #1 in mammography CAD by MD Buyline's User Satisfaction Report for the first two quarters of 2008.

-- Company issued stock in full payment of remaining $3.0 million in convertible promissory notes.

"We are proud of the impressive results achieved in all areas of our business during the third quarter of 2008, including record revenues, strong earnings, improved gross margin and solid cash flow," commented Ken Ferry, iCAD's President and CEO. "Revenue growth was led by record digital sales, which reflect the continued transition of the mammography market from film-based technology to digital technology. We remain optimistic about future growth as only about 43% of the approximately 13,500 mammography systems in the U.S. had transitioned to digital as of the close of the quarter."

Commenting on the recently completed asset acquisition of CAD Sciences, Mr. Ferry said, "We are delighted to report that within 60 days of closing on the asset acquisition we completed the rigorous re-branding, training and re-launch of SpectraLook and VividLook, innovative kinetics technology integrated into iCAD's image analysis solutions for breast and prostate MRI studies, and CADvue(TM), image review and analysis software designed to improve the analysis workflow, interventional planning and reporting of breast MRI results. This accomplishment underscores the successful integration of this asset acquisition and is testament to the hard work and dedication of our talented team of engineers, operations and marketing professionals."

"We continue to be excited about our pipeline of products and remain on track for completion of the clinical reader study of our colon CAD product late this year or early next, after which we will file an application with the FDA. We anticipate an international release for this product in tandem with the U.S. FDA filing," he added.

Third Quarter Results

Total revenue for the third quarter of 2008 was $11.2 million, a 79% increase compared with total revenue of $6.3 million for the third quarter of 2007. This increase reflects a $4.2 million increase in revenue of the Company's digital products. The Company realized revenue increases from all of their OEM partner sales, and specifically the sale of its SecondLook Digital product for use with Fujifilm's Computed Radiography for Mammography systems, which benefited from a combination of new sales and pent-up demand from Fujifilm's installed base of customers and from sales to the Company's newest partner in Europe, Denmark-based Sectra.

Strong film-based revenue in the quarter reflects continued outstanding market acceptance of TotalLook MammoAdvantage(TM), which was launched late in the first quarter of 2008. The increase in service and supply revenue is largely the result of new service contracts for digital products that have come off warranty. The Company expects continued growth in this area as digital CAD systems sales grow and products transition from warranty to service contracts.

The gross margin for the third quarter of 2008 increased to 84.1% from 80.1% in the prior-year third quarter. For the third quarter of 2008, the Company posted net income, including stock-based compensation expense of $538,000, of $2.1 million or $0.04 per diluted share, compared with a net loss, including stock-based compensation expense of $363,000, of ($682,000) or ($0.02) per share in the third quarter of 2007.

For the third quarter of 2008, sales of iCAD's digital products increased 104% to $8.2 million from $4.0 million in the prior-year period. Sales of film-based products increased 48% to $2.2 million from $1.5 million, and service and supply revenue increased 9% to $871,119 from $800,765, both compared with third quarter 2007 results.

                                Three months ended September 30,
                                2008                    2007                   % Change
Digital revenue                 $     8,155,673         $     3,989,826        104.4  %
Film based revenue                    2,166,839               1,468,950        47.5   %
Service & supply revenue              871,119                 800,765          8.8    %
Total revenue                   $     11,193,631        $     6,259,541        78.8   %

Nine Month Results

For the nine months ended September 30, 2008, total revenue increased 52% to $28.2 million compared with total revenue of $18.5 million for the nine months ended September 30, 2007. The gross margin for the first nine months of 2008 increased to 83.5% from 80.1% in the comparable prior-year period. Net income for the nine months ended September 30, 2008, including stock-based compensation expense of $1,355,000, increased to $4.0 million or $0.09 per diluted share, compared with a net loss, including stock-based compensation expense of $856,000, of ($2.1 million), or ($0.06) per share, for the nine months ended September 30, 2007.

For the first nine months of 2008, sales of iCAD's digital solutions increased 79% over the prior-year period to $20.4 million from $11.4 million. Film-based product sales of $5.3 million were 14% higher than the $4.6 million of film based product sales recorded during the first nine months of 2007, and service and supply revenue of $2.5 million was essentially unchanged compared with the first nine months of 2007.

                                Nine months ended September 30,
                                2008                  2007                  % Change
Digital revenue                 $    20,403,283       $    11,405,076       78.9  %
Film based revenue                   5,250,976             4,588,106        14.4  %
Service & supply revenue             2,520,877             2,518,581        0.1   %
Total revenue                   $    28,175,136       $    18,511,763       52.2  %

Commenting on the balance sheet, Darlene Deptula-Hicks, Executive Vice President and CFO, said, "During the third quarter of 2008 we continued to strengthen our balance sheet and marked our fifth consecutive quarter of positive cash flow. During the quarter we generated more than $3.9 million in cash largely as a result of our ability to scale revenue while controlling expenses and to a lesser degree as a result of cash received from employee stock option exercises. In addition, we issued stock in full payment of the remaining $3 million in convertible promissory notes, and remitted a $2 million cash payment due on the closing of the CAD Sciences asset acquisition."

As of September 30, 2008, iCAD had cash and cash equivalents of $11.0 million, compared with $4.3 million as of December 31, 2007. Quarter-end inventories were essentially unchanged compared with year-end 2007. Accounts payable were $1.8 million, down from $2.0 million, and accounts receivable decreased to $6.0 million from $6.5 million as of December 31, 2007.

2008 Financial Guidance

iCAD today announces that its financial guidance for the full-year 2008, remains consistent with previous guidance announced in July. The Company anticipates total revenue for the year to be between $38 million to $39 million. The Company also expects to achieve gross margin of better than 83.5%, and anticipates operating expenses for the year to be between $26.3 million and $27.1 million. These operating expenses include approximately $2.0 million in spending for a combination of the integration and other costs associated with the asset acquisition, which includes revamping the "go to market" strategy for the Breast and Prostate MRI CAD products and continued preparations for the re-launch of these products, along with the costs associated with the clinical trial for the Company's colon CAD product, which is underway in partnership with ACR Image Matrix. The Company expects net income for the full year to be between $4.6 million and $5.0 million.

Conference Call

iCAD management will host an investment community conference call beginning at 10:00 a.m. Eastern time on Thursday, October 30, 2008 to discuss these results and to answer questions. The conference call will be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com or www.icadmed.com. Stockholders and other interested parties may participate in the conference call by dialing 800-706-7749 (domestic) or +617-614-3474 (international) and entering passcode 33654365.

A replay of the conference call will be accessible two hours after its completion through November 6, 2008 by dialing 888-286-8010 (domestic) or +617-801-6888 (international) and entering passcode 66260039. The call and PowerPoint presentation will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com and www.icadmed.com.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Currently available in more than 2,200 healthcare centers worldwide, iCAD's solutions aid in the early detection of the most prevalent cancers including breast, colon, prostate and in the future, lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release, including but not limited to, statements about the Company's confidence or strategies or expectations about revenues, results of operations, timing of regulatory approval of products or market opportunities, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

iCAD, Inc.
Consolidated Statements of Operations
(unaudited)
                                                       Three Months                                Nine Months
                                                       September 30,                               September 30,
                                                            2008                  2007                  2008                  2007
Revenue
Products                                               $    10,322,512       $    5,458,776        $    25,654,259       $    15,993,182
Service and supplies                                        871,119               800,765               2,520,877             2,518,581
Total revenue                                               11,193,631            6,259,541             28,175,136            18,511,763
Cost of revenue
Products                                                    1,588,501             1,010,884             4,014,143             2,962,174
Service and supplies                                        193,451               237,121               639,834               712,652
Total cost of revenue                                       1,781,952             1,248,005             4,653,977             3,674,826
Gross margin                                                9,411,679             5,011,536             23,521,159            14,836,937
Operating expenses:
Engineering and product development                         1,905,841             1,129,345             4,818,645             3,327,644
Marketing and sales                                         3,340,072             2,620,827             8,533,061             7,923,032
General and administrative                                  1,942,582             1,816,657             5,726,819             5,319,963
Total operating expenses                                    7,188,495             5,566,829             19,078,525            16,570,639
Income (loss) from operations                               2,223,184             (555,293)             4,442,634             (1,733,702)
Interest expense - net                                      27,610                114,752               210,314               329,891
Net income (loss) before provision for income taxes    $    2,195,574        $    (670,045)        $    4,232,320        $    (2,063,593)
Provision for income taxes                                  101,000               -                     197,000               -
Net income (loss)                                           2,094,574             (670,045)             4,035,320             (2,063,593)
Preferred dividend                                          -                     11,880                -                     67,760
Net income (loss) attributable to common stockholders  $    2,094,574        $    (681,925)        $    4,035,320        $    (2,131,353)
Net income (loss) per share
Basic                                                  $    0.05             $    (0.02)           $    0.10             $    (0.06)
Diluted                                                $    0.04             $    (0.02)           $    0.09             $    (0.06)
Weighted average number of shares used
in computing income (loss) per share
Basic                                                       42,953,932            38,707,772            40,487,297            38,076,299
Diluted                                                     46,578,716            38,707,772            45,241,275            38,076,299

iCAD, INC. AND SUBSIDIARY
Consolidated Balance Sheets
(unaudited)
                                                               September 30,              December 31,
                                                               2008                       2007
Assets (Note 2)
Current assets:
Cash and cash equivalents                                      $       11,049,682         $       4,348,729
Trade accounts receivable, net of allowance for doubtful
accounts of $50,000 in 2008 and 2007                                   6,016,104                  6,483,618
Inventory, net                                                         1,813,523                  1,798,243
Prepaid and other current assets                                       559,679                    320,169
Total current assets                                                   19,438,988                 12,950,759
Property and equipment:
Equipment                                                              3,763,567                  3,512,557
Leasehold improvements                                                 75,590                     71,611
Furniture and fixtures                                                 356,497                    330,077
Marketing assets                                                       234,140                    323,873
                                                                       4,429,794                  4,238,118
Less accumulated depreciation and amortization                         2,761,510                  2,369,590
Net property and equipment                                             1,668,284                  1,868,528
Other assets:
Deposits                                                               63,194                     63,194
Patents, net of accumulated amortization                               21,977                     68,269
Customer relationships, net of accumuated amortization                 242,833                    -
Technology intangibles, net of accumulated amortization                7,401,480                  3,115,843
Tradename, net of accumulated amortization                             130,200                    148,800
Goodwill                                                               43,515,285                 43,515,285
Total other assets                                                     51,374,969                 46,911,391
Total assets                                                   $       72,482,241         $       61,730,678
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable                                               $       1,809,829          $       2,010,717
Accrued salaries and other expenses                                    3,079,179                  3,461,422
Deferred revenue                                                       2,129,772                  1,674,005
Convertible loans payable to related parties                           -                          2,793,382
Convertible loans payable to non-related parties                       -                          684,559
Total current liabilities                                              7,018,780                  10,624,085
Convertible revolving loans payable to related party                   -                          2,258,906
Total liabilities                                                      7,018,780                  12,882,991
Commitments and contingencies
Stockholders' equity:
Common stock, $ .01 par value: authorized 85,000,000
shares; issued 45,411,384 in 2008 and 39,239,208
in 2007; outstanding 45,343,508 in 2008 and
39,171,332 in 2007                                                     454,113                    392,392
Additional paid-in capital                                             147,574,151                135,055,418
Accumulated deficit                                                    (81,614,539)               (85,649,859)
Treasury stock at cost (67,876 shares)                                 (950,264)                  (950,264)
Total Stockholders' equity                                             65,463,461                 48,847,687
Total liabilities and stockholders' equity                     $       72,482,241         $       61,730,678

SOURCE: iCAD, Inc.

iCAD 
Darlene Deptula-Hicks, 603-882-5200 x7944 
EVP and CFO 
ddeptula@icadmed.com 
or 
Investor Relations 
Lippert/Heilshorn & Associates 
Anne Marie Fields, 212-838-3777 x6604 
afields@lhai.com 
or 
Public Relations 
MS&L 
Meara Murphy, 617-937-2574 
meara.murphy@mslworldwide.com